Solventum Co. (NYSE:SOLV) Shares Sold by Mariner LLC

Mariner LLC decreased its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 65,614 shares of the company's stock after selling 6,008 shares during the quarter. Mariner LLC's holdings in Solventum were worth $4,334,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SOLV. Norges Bank purchased a new stake in Solventum in the fourth quarter valued at approximately $203,740,000. Boston Partners purchased a new stake in shares of Solventum in the 4th quarter valued at $110,378,000. Independent Franchise Partners LLP lifted its stake in Solventum by 105.0% during the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company's stock worth $105,904,000 after acquiring an additional 821,272 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock valued at $43,902,000 after acquiring an additional 431,986 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Solventum by 41.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company's stock valued at $78,833,000 after acquiring an additional 347,669 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SOLV. Piper Sandler increased their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Morgan Stanley upped their price objective on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. Wells Fargo & Company lifted their target price on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Finally, Bank of America upped their price target on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, Solventum presently has a consensus rating of "Hold" and an average price target of $79.86.

Solventum Stock Up 1.6 %

Solventum stock traded up $1.01 during midday trading on Wednesday, reaching $65.95. The company's stock had a trading volume of 639,849 shares, compared to its average volume of 1,314,419. The company has a market cap of $11.41 billion and a P/E ratio of 23.98. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business has a 50-day simple moving average of $73.04 and a 200-day simple moving average of $71.60. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.